Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: Results of the RELIEF study

Infection

Volumn 41, Issue 1, 2013, Pages 175-186

  Schaper, N C ^a   Dryden, M ^b   Kujath, P ^c   Nathwani, D ^d   Arvis, P ^e   Reimnitz, P ^f   Alder, J ^g   Gyssens, I C ^h,i,j  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^c University Clinic of Luebeck   (Germany)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Bayer HealthCare ^*  (France)

^f BAYER PHARMA AG   (Germany)

^g BAYER CORPORATION   (United States)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^j HASSELT UNIVERSITY   (Belgium)

more..

Author keywords

Antibiotic therapy; Controlled clinical trial; Diabetic foot infection; Diabetic foot ulcer; Fluoroquinolone; Moxifloxacin; Sequential therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABSCESS; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMOGRAPHY; DIABETIC FOOT; DIABETIC FOOT INFECTION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GANGRENE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY (TOPIC); NAUSEA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SIDE EFFECT; SKIN INFECTION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA; BACTERIAL INFECTIONS; DIABETIC FOOT; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; QUINOLINES; TREATMENT OUTCOME;

EID: 84873741070     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0367-x     Document Type: Article

References (43)

1. Joseph WS, Lipsky BA. Medical therapy of diabetic foot infections. J Am Podiatr Med Assoc. 2010;100:395-400.
2. Nelson SB. Management of diabetic foot infections in an era of increasing microbial resistance. Curr Infect Dis Rep. 2009;11:375-82.
3. Nicolau DP, Stein GE. Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. J Am Podiatr Assoc. 2010;100:52-63.
4. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29:1288-93.
5. Tentolouris N, Al-Sabbagh S, Walker MG, Boulton AJM, Jude EB. Mortality in diabetic and nondiabetic patients after amputations performed from 1990 to 1995: a 5-year follow-up study. Diabetes Care. 2004;27:1598-604.
6. Khanolkar MP, Bain SC, Stephens JW. The diabetic foot. QJM. 2008;101:685-95.
7. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale Study. Diabetologia. 2007;50:18-25.
8. McClaine RJ, Husted TL, Hebbeler-Clark RS, Solomkin JS. Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections. Clin Infect Dis. 2010;50:1120-6.
9. Citron DM, Goldstein EJC, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45:2819-28.
10. Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. 1981;2:64-122.
11. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surg. 1996;35:528-31.
12. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998;21:855-9.
13. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20(Suppl 1):S90-5.
14. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39:885-910.
15. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis. 2007;44:562-5.
16. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. 2004;48:1012-6.
17. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(Suppl B):83-90.
18. Müller M, Stass H, Brunner M, Möller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother. 1999;43:2345-9.
19. Majcher-Peszynska J, Sass M, Schipper S, et al. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. Eur J Clin Pharmacol. 2011;67:135-42.
20. Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother. 1999;43:1508-10.
21. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. 2007;60:370-6.
22. Gyssens IC, Dryden M, Kujath P, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother. 2011;66:2632-42.
23. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366:1695-703.
24. Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg. 2003;185:369-75.
25. Schaper N, Dryden M, Kujath P et al. Efficacy of moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study (abstract). Presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 10-13 April 2010, P1550.
26. Uzun G, Solmazgul E, Curuksulu H, et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med. 2007;213:305-12.
27. Nather A, Chionh SB, Han AY, Chan PP, Nambiar A. Effectiveness of vacuum-assisted closure (VAC) therapy in the healing of chronic diabetic foot ulcers. Ann Acad Med Singapore. 2010;39:353-8.
28. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis. 2002;35:381-9.
29. Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin- clavulanate. Clin Infect Dis. 2004;38:17-24.
30. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26:357-65.
31. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46:647-55.
32. Crouzet J, Lavigne JP, Richard JL, Sotto A; Nîmes University Hospital Working Group on the Diabetic Foot (GP30). Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. Int J Infect Dis. 2011;15:e601-10.
33. Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt). 2005;6:27-40.
34. Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med. 2001;18:229-34.
35. Prompers L, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51:747-55.
36. Hirschl M, Kundi M, Hirschl AM, Georgopoulos A. Effects of macro- and microcirculatory functions on ceftriaxone concentrations in tissues of patients with stage IV peripheral arterial occlusive disease. Antimicrob Agents Chemother. 1995;39:15-9.
37. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007;60:819-23.
38. Zammit MC, Fiorentino L, Cassar K, Azzopardi LM, LaFerla G. Factors affecting gentamicin penetration in lower extremity ischemic tissues with ulcers. Int J Low Extrem Wounds. 2011;10:130-7.
39. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection. 2009;37:407-17.
40. Matthews PC, Berendt AR, Lipsky BA. Clinical management of diabetic foot infection: diagnostics, therapeutics and the future. Expert Rev Anti Infect Ther. 2007;5:117-27.
41. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med. 2003;20:159-61.
42. Lecornet E, Robert J, Jacqueminet S, et al. Preemptive isolation to prevent methicillin-resistant Staphylococcus aureus cross-transmission in diabetic foot. Diabetes Care. 2007;30:2341-2.
43. Edmonds M. The treatment of diabetic foot infections: focus on ertapenem. Vasc Health Risk Manage. 2009;5:949-63.